Inventor
BENGTSSON TORE
SE14 patents
⚠️ This page may combine multiple inventors who share the name “BENGTSSON TORE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ATROGI AB
10 patentsUS10288602B2May 14, 2019
Screening method, a kit, a method of treatment and a compound for use in a method of treatement
ATROGI AB7 citations82
US9891212B2Feb 13, 2018
Screening method, a kit, a method of treatment and a compound for use in a method of treatment
ATROGI AB8 citations82
US9784726B2Oct 10, 2017
Screening method, a kit, a method of treatment and a compound for use in a method of treatment
ATROGI AB8 citations82
US9657348B2May 23, 2017
Method of screening compounds for the treatment of diabetes
ATROGI AB9 citations82
US11427539B2Aug 30, 2022
Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
ATROGI AB3 citations71
US12280023B2Apr 22, 2025
Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
ATROGI AB0 citations61
US12036210B2Jul 16, 2024
Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
ATROGI AB0 citations61
US11648216B2May 16, 2023
Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
ATROGI AB1 citations61
US12378216B2Aug 5, 2025
Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia
ATROGI AB0 citations50
US11793774B2Oct 24, 2023
Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
ATROGI AB0 citations50
SIGRID THERAPEUTICS AB
3 patentsUS12492129B2Dec 9, 2025
Highly structured porous silica materials and biological uses thereof
SIGRID THERAPEUTICS AB0 citations53
US12121612B2Oct 22, 2024
Porous silica material for use as a pharmaceutical or dietary active ingredient
SIGRID THERAPEUTICS AB0 citations50
US10695294B2Jun 30, 2020
Porous silica material for use as a pharmaceutical or dietary active ingredient
SIGRID THERAPEUTICS AB1 citations50